Using a home app for wet age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This study tests whether using a smartphone app to monitor your vision at home can help manage wet age-related macular degeneration (AMD) while you continue your usual treatment. The app may help you and your doctor spot changes early, so you can adjust treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 55 years old or older.
- You have wet (exudative) age-related macular degeneration (AMD) in the study eye.
- You are new to treatment or have been receiving anti-VEGF injections (such as aflibercept, ranibizumab, or bevacizumab) for less than 48 weeks.
- Your vision in the study eye is between roughly 20/20 and 20/200 (as measured by a standard eye chart).
- You must own a compatible smartphone or tablet and be able to use the OKKO Health app after training.
- You must not have other eye conditions that could interfere with the study, such as diabetic macular edema or retinal vein occlusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a web-based eye-tracking tool to monitor vision impairment in people with wet age-related macular degeneration (AMD). You would use your computer at home, which could help reduce the need for frequent clinic visits.
This study tests a home monitoring system using a webcam to check for signs of wet AMD returning. It may help you manage your condition between doctor visits and catch problems early.
This Phase 4 study tests an artificial-intelligence (AI) system used in real-world care for people with “wet” age-related macular degeneration. The goal is to help doctors monitor and treat the eye more accurately and safely over time.
This study tests a new eye drop treatment for people with wet age-related macular degeneration (AMD) who have already been treated with standard injections. The goal is to see if this new treatment can help maintain or improve vision and reduce the need for injections.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
Hear when a new Exudative Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.